ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Apr 2, 2018
Why Some Investors Fail -- Worms!
Image Source: crabchick. When you read our research, we’re not just providing financial metrics -- Valuentum is striving to provide an answer to the most important question in investing: what is a company worth? Though there are varying opinions about which underlying factor is the most important investment consideration, at the end of the day, the process of valuation collects every investment consideration to provide a conclusion. It is the answer after all other considerations, the final outcome of analysis. It is why we say that investors that don't pay attention to valuation may be doomed to fail...eventually. Not seeking valuation is not seeking the answer.
Mar 28, 2018
PCSK9 Woes Weigh on Amgen and Regeneron
Image shown: Amgen and Regeneron have both meaningfully trailed the market since October of 2017. The robustness of the clinical pipeline offers an important clue regarding the health and vitality of a biotech/pharma company, as the clinical pipeline is critical towards maintaining and growing the top line. One of the most promising, and dare-we-say, overhyped new treatments to enter the market is the PCSK9 cholesterol-lowering agents, with Amgen and Regeneron leading the pack. Let’s discuss the results of Regeneron’s treatment along with a discussion of the path forward for the treatment.
Mar 15, 2018
Nearly 60 Distribution Cuts Later, We Maintain Our View on the Hazards of the MLP Business Model
Image Source: Brian Cantoni. Valuentum has been highlighting the inherent risks associated with the master limited partnership (MLP) structure for some time now, but we are not alone in acknowledging the limited sustainability of such structures. Internal simplification transactions may only become more common moving forward as management teams seek to optimize the structure of their entities.
Feb 8, 2018
The Turnaround at Novartis Has Begun
Image Source: Novartis. We believe Novartis is poised to accelerate from the patent cliff caused by the loss of protection of Gleevec, its former top-selling product. The company has a stellar dividend growth history, and the market is anticipating a turnaround once it anniversaries the patent cliff.
Dec 14, 2017
Video: What Cash Flow Are You Talking About?
President of Investment Research Brian Nelson reviews important topics from the first six episodes of "Off the Cuff," and goes into great detail about all the intricacies of "cash flow" from traditional free cash flow to enterprise free cash flow valuation. You know you want to watch. Running Time: ~14 minutes.
Dec 11, 2017
Omega Healthcare and Holly Energy Partners: Case Studies in REIT and MLP Income Evaluation
Image shown: The performance of the Vanguard REIT ETF (VNQ) during the Financial Crisis in 2007-2009. An assessment of a REIT’s or MLP’s dividend/distribution strength not only should reflect firm-specific fundamentals, but also external market conditions, which are paramount to the sustainability of most any REIT’s or MLP’s payout. Let’s remind readers of this important dynamic, which is captured via the two different Dividend Cushion ratios, and walk through what goes into the analysis we pursue when making a change with respect to our assessment of a company’s dividend health or safety.
Dec 1, 2017
Dividend Increases/Decreases for the Week Ending December 1
Let's take a look at companies raising/lowering their dividends this week.
Nov 17, 2017
Celgene Implodes
The pharma/biotech industry operates in a boom-bust environment where the market cap of a company can post a meteoric rise or suffer a precipitous fall based on the data published from recently completed clinical trials. The industry remains one of the most innovative fields, but the quest for new products leads to constant disruption and a subsequent spike in volatility. Of late, the volatility pendulum for Celgene has swung in favor of the bears with the company posting a costly phase 3 failure.
Oct 31, 2017
Novartis Gearing Up for Growth
 Image Source: Novartis. Dividend Growth Newsletter portfolio idea Novartis continues to grow its free cash flow stream while producing a string of products still in the infancy of their respective growth curves. The pharma/biotech realm remains bedeviled with patent issues that can disrupt cash flow generation once protection is lost, causing us to look for companies positioned for a fresh leg of growth. To that end, let’s take a look at Novartis’ pipeline, near-term potential, and how it relates to its dividend health.
Oct 25, 2017
Kinder Morgan Versus Enterprise Products Partners?
Image Source: Stefan Baudy. Question: Valuentum's latest note on Kinder Morgan hinted the company's situation is improving, even though its ratings are weaker than Enterprise Products Partners'. Would you please compare these companies? Is Valuentum saying Kinder Morgan is a better bet than Enterprise Products Partners because Kinder Morgan is a corporation and not an master limited partnership?


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.